title: BCL2 protein expression in follicular lymphomas with t(14;18) chromosomal translocations.
abstract: The t(14;18)(q32;q21) chromosomal translocation induces BCL2 protein overexpression in most follicular lymphomas. However the expression of BCL2 is not always homogeneous and may demonstrate a variable degree of heterogeneity. This study analysed BCL2 protein expression pattern in 33 cases of t(14;18)-positive follicular lymphomas using antibodies against two different epitopes (i.e. the widely used antibody BCL2/124 and an alternative antibody E17). 16/33 (49%) cases demonstrated strong BCL2 expression. In 10/33 (30%) cases, BCL2 expression was heterogeneous and in some of these, its loss appeared to be correlated with cell proliferation, as indicated by Ki67 expression. Double immunofluorescence labelling confirmed an inverse BCL2/Ki67 relationship, where in 24/28 (86%) cases cellular expression of BCL2 and Ki67 was mutually exclusive. In addition, seven BCL2 'pseudo-negative' cases were identified in which immunostaining was negative with antibody BCL2/124, but positive with antibody E17. Genomic DNA sequencing of these 'pseudo-negative' cases demonstrated eleven mutations in four cases and nine of these were missense mutations. It can be concluded that in follicular lymphomas, despite carrying the t(14;18) translocations, BCL2 protein expression may be heterogeneous and loss of BCL2 could be related to cell proliferation. Secondly, mutations in translocated BCL2 genes appear to be common and may cause BCL2 pseudo-negative immunostaining.
authors.affiliation: Pathology Department, Faculty of Medicine, Universiti Kebangsaan Malaysia Medical Centre, Kuala Lumpur, Malaysia. noraidah@mail.hukm.ukm.my
authors.forename: Noraidah
authors.initials: N
authors.lastname: Masir
authors.forename: Lisa J
authors.initials: LJ
authors.lastname: Campbell
authors.forename: Lindsey K
authors.initials: LK
authors.lastname: Goff
authors.forename: Margaret
authors.initials: M
authors.lastname: Jones
authors.forename: Teresa
authors.initials: T
authors.lastname: Marafioti
authors.forename: Jacqueline
authors.initials: J
authors.lastname: Cordell
authors.forename: Andrew J
authors.initials: AJ
authors.lastname: Clear
authors.forename: T Andrew
authors.initials: TA
authors.lastname: Lister
authors.forename: David Y
authors.initials: DY
authors.lastname: Mason
authors.forename: Abigail M
authors.initials: AM
authors.lastname: Lee
mesh_terms: D014408:Biomarkers, Tumor / Q000032:analysis*; D049109:Cell Proliferation; D002883:Chromosomes, Human, Pair 14; D002887:Chromosomes, Human, Pair 18; D004252:DNA Mutational Analysis; D019254:Genes, bcl-2; D006801:Humans; D007150:Immunohistochemistry; D017404:In Situ Hybridization, Fluorescence / Q000379:methods; D019394:Ki-67 Antigen / Q000032:analysis; D008224:Lymphoma, Follicular / Q000235:genetics / Q000378:metabolism*; D009154:Mutation; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000032:analysis*; D014178:Translocation, Genetic
chemical_list: D014408:Biomarkers, Tumor; D019394:Ki-67 Antigen; D019253:Proto-Oncogene Proteins c-bcl-2